Plain-English translation of NCT07297589 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether dapagliflozin or semaglutide can help reduce the amount of fat that builds up around the heart in people recovering from a heart attack. Researchers will measure this heart fat using CT scans at the start of the study and again after one year of treatment. The goal is to understand which medication may offer better protection for heart health after a serious cardiac event.
Heart attacks often leave damage and inflammation, and extra fat around the heart can make recovery harder and increase the risk of future heart problems. This study aims to find out which of these two medications works better at reducing that harmful fat and supporting long-term heart health.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take one of the two medications daily starting after your hospital discharge. You'll visit the clinic for follow-up care and medication monitoring over 12 months, and you'll have CT scans of your heart at the beginning and at the end of the study to measure changes in the fat around your heart. The research team will check how well you're tolerating the medication and how closely you're able to take it as prescribed.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Mexico